Direct answer: In November 2025, the FDA removed its strongest safety warning, the "black box" label, from estrogen containing menopause hormone therapy products, a warning that had been in place since 2002. The agency said newer research shows that for most women who start therapy near the onset of menopause, the risk picture looks different than the one that label described for more than two decades.
Key Takeaways
The FDA removed the 22-year-old black box warning from estrogen based menopause hormone therapy in November 2025.
The original warning came from a 2002 study that grouped women ages 50 to 79 into one risk pool, which blurred real differences in risk by age and time since menopause.
Newer analysis points to a "timing hypothesis": starting therapy closer to menopause onset, generally before age 60 or within about ten years of your last period, appears to carry a different risk and benefit profile than starting it much later.
Early data presented in late 2025 suggested lower rates of certain outcomes among women who started therapy earlier, but this is preliminary, not yet a peer reviewed, settled conclusion.
This is a regulatory and research update, not medical advice. Your personal history still needs a conversation with a licensed provider.
In This Article
What exactly changed with the FDA's hormone therapy warning?
Why did hormone therapy get a black box warning in the first place?
What is the "timing hypothesis," and what does the newer research say?
Does this mean hormone therapy is risk free now?
What does this actually change for you?
A quick scope of practice note
FAQ
What exactly changed with the FDA's hormone therapy warning?
On November 10, 2025, the FDA announced it would remove the black box warning, its strongest category of safety label, from more than 20 prescription pills, patches, and creams that contain estrogen or progestin and are used to treat menopause symptoms like hot flashes and night sweats. FDA Commissioner Marty Makary described the warning as outdated, saying it had discouraged women from using a treatment that could genuinely help them. HHS Secretary Robert F. Kennedy Jr. framed the move as "recommitting to evidence based medicine," in the agency's own words.
The FDA reportedly skipped its usual public advisory panel process for this change, which a few outlets and clinicians have noted as unusual, even among people who otherwise welcomed the outcome. That matters less for what the label now says and more for how much deliberation happened before it changed, worth knowing as context, not a reason to distrust the update itself.
Why did hormone therapy get a black box warning in the first place?
The warning traces back to the Women's Health Initiative (WHI), a large federal study of more than 26,000 women published starting in 2002. Early WHI findings linked combined hormone therapy to increased risk of blood clots, stroke, heart problems, and, in some analyses, dementia. Prescriptions for hormone therapy dropped sharply across every age group almost immediately, and estrogen went from something roughly one in four American women over 50 used in the 1990s to something many women and their doctors avoided entirely.
The problem researchers kept circling back to over the following two decades: the original WHI cohort lumped women ages 50 to 79 together as though their bodies and risk profiles were the same. A 55 year old within a few years of her last period and a 75 year old two decades past menopause are starting from very different baselines, hormonally and cardiovascularly. Later reanalysis of that same WHI data, conducted by other research teams over the years, suggested that for younger participants closer to menopause onset, the benefit to risk balance looked considerably better than the headline findings implied. That reanalysis took years to filter into mainstream medical guidance, and the black box warning itself never caught up to it.
What is the "timing hypothesis," and what does the newer research say?
The idea now driving most of this conversation in menopause research is sometimes called the "timing hypothesis": that when you start hormone therapy relative to your final menstrual period may matter as much as, or more than, whether you start it at all.
One of the more widely discussed recent data sets came from a team at Case Western Reserve University, presented at the Menopause Society's 2025 Annual Meeting. Researcher Ify Chidi, working with OB-GYN and associate professor Dr. Rachel Pope, analyzed more than 60 million patient records and compared outcomes for women who started hormone therapy before menopause, at the onset of menopause, and never. In that analysis, women who started therapy in the ten years before menopause had a notably lower incidence of breast cancer compared to women who never used hormone therapy, with a modest increase in heart attack and stroke incidence, both groups' numbers staying under 10 percent. Women who started therapy right at the onset of menopause showed an even larger reduction in breast cancer incidence in this data set, again with a similarly modest increase in cardiovascular outcomes.
It's worth sitting with how preliminary that is. This was data presented at a professional conference, not yet a peer reviewed published study with the full statistical detail (confidence intervals, significance testing) that lets researchers call something settled. Chidi herself has said that definitive recommendations still require further clinical and randomized trials. Part of what the data shows may also simply reflect that the perimenopausal group was younger and hadn't lived long enough yet to develop some of these outcomes either way. Promising, directionally consistent with the timing hypothesis, and not yet proof.
Does this mean hormone therapy is risk free now?
No, and no credible source involved in this story has claimed that. The FDA's own reasoning for the label change centered on timing: officials pointed to research suggesting hormone therapy carries comparatively few risks when started before age 60 and within about ten years of a woman's last menstrual period. Outside that window, the research this label change leaned on doesn't really speak to your situation one way or another.
Personal and family history still matters enormously. A history of blood clots, stroke, heart attack, hormone sensitive cancers (including certain breast cancers), or liver disease generally still rules hormone therapy out or requires much more careful management, label change or not. None of that changed in November 2025. What changed is that the conversation about trying it, for women in the window the research actually covers, now starts from a more accurate, less frightening baseline than a 22 year old warning label was giving anyone.
What does this actually change for you?
Practically, probably less than the headlines made it sound, and that's not nothing. If you've avoided bringing up hot flashes, sleep disruption, mood changes, or irregular cycles with your doctor because you'd absorbed, correctly, that hormone therapy sounded dangerous, this is a legitimate reason to revisit that conversation. You're not behind. The information genuinely changed.
This also isn't a reason to start anything without your provider, or to assume a TikTok video or a wellness brand (including this one) can tell you whether hormone therapy fits your specific history. What it is: permission to ask the question out loud, armed with a more current picture than the one most of us grew up hearing.
A quick scope of practice note
I'm a certified health coach, not a physician, and nothing here is medical advice or a recommendation to start, stop, or change any hormone therapy or medication. Decisions about hormone therapy belong to you and a licensed medical provider who knows your full history. What I can do, and what this piece is for, is help you walk into that conversation with accurate, current information instead of two decades of fear doing the talking. If you're managing perimenopause or menopause symptoms right now, my coaching work focuses on the nervous system, sleep, and daily rhythm side of that experience, the parts that sit alongside whatever medical path you and your doctor choose, not instead of it.
FAQ
What did the FDA actually remove from hormone therapy labels?
The FDA removed the "black box warning," its most serious safety label category, from more than 20 estrogen or progestin containing prescription products used to treat menopause symptoms. The warning had been in place since shortly after the 2002 Women's Health Initiative findings were published.
Is hormone therapy now recommended for all menopausal women?
No. The research behind this label change points to a more favorable risk and benefit balance specifically for women who start therapy before age 60 or within about ten years of their final period. It says little about women outside that window, and personal and family medical history still determines whether hormone therapy is appropriate for any individual.
What is the "timing hypothesis" in menopause research?
It's the idea that when hormone therapy is started, relative to a woman's final menstrual period, may affect its risk and benefit profile as much as whether it's started at all. Several research teams have found that starting earlier, closer to menopause onset, tends to look more favorable than starting many years later.
Does this mean the original 2002 warning was wrong?
Not exactly wrong, but incomplete. The original study found real risks in its overall study population. The issue researchers identified afterward was that averaging outcomes across women ages 50 to 79 obscured how differently risk behaves depending on a woman's age and years since menopause, something later reanalysis and newer research have tried to correct for.
Should I start hormone therapy because of this news?
That's a decision for you and a licensed medical provider, based on your personal and family health history, current symptoms, and goals. This article is meant to inform that conversation, not replace it.
About the Author
Kara Ryles is an ACE Certified Health Coach and the founder of The Wellness Shift Co., where she works with high responsibility women in their 30s, 40s, and 50s navigating perimenopause, burnout, and the nervous system toll of carrying professional, caregiving, and community responsibility at once. Before coaching, Kara spent nearly 20 years in federal acquisitions and executive leadership, including her own experience moving through burnout and hormonal shifts while still showing up for a demanding career. She built The Wellness Shift Co. and the S.H.I.F.T. Method on the belief that women managing high stakes responsibility deserve wellness guidance grounded in both research and real life, not generic advice written for a different season of life entirely.
